Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Precision BioSciences, Inc.

< Previous 1 2 3 4 5 Next >
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Participate in Upcoming November Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Third Quarter Results on November 4, 2024
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Participate in Upcoming August Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Second Quarter Results on August 1, 2024
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.